Harnessing a Natural Mechanism to Silence Disease

Mark Rothera, who at the time served as CEO of Silence Therapeutics and Giles Campion, Silence’s chief medical officer and head of R&D, discuss the company’s platform technology, why it can be used to target a broad range of genetic diseases, and the company’s programs in development.